IDEAYA/Servier PKC Drug Aces Uveal Melanoma Trial

Why It Matters

The trial fills a critical therapeutic gap for HLA‑A*02:01‑negative uveal melanoma, a segment with no approved drugs, and could generate up to $800 million in annual revenue.

Key Takeaways

• Darovasertib + crizotinib doubled median PFS to 6.9 months.
• Objective response rate rose to 37.1% versus 5.8% control.
• Targets ~1,500 U.S. HLA‑A*02:01‑negative metastatic patients.
• Potential peak revenue estimated at $800 million annually.

Pulse Analysis

Uveal melanoma, the most common primary eye cancer in adults, accounts for roughly 5% of all melanoma cases but carries a dismal prognosis once it spreads. The disease is driven by GNAQ/11 mutations that activate PKC signaling, yet treatment options have been limited to immunotherapies that work only for a minority of patients with the HLA‑A*02:01 allele. For the roughly 50‑70% of metastatic patients who are HLA‑A*02:01‑negative, no FDA‑approved therapy exists, creating a high‑unmet‑need niche that investors and biotech firms have been eyeing for years.

The OptimUM‑02 study delivered the first randomized evidence that a PKC inhibitor can meaningfully extend progression‑free survival in this population. By pairing darovasertib with crizotinib, a cMET inhibitor, the regimen more than doubled median PFS to 6.9 months and lifted the objective response rate to 37.1%, far surpassing the 3.1‑month PFS and 5.8% response seen with standard immunotherapy choices. With an estimated 3,000 U.S. uveal melanoma patients and about half progressing to metastatic disease, the addressable market for HLA‑A*02:01‑negative patients approaches 1,500 individuals, comparable to the market for tebentafusp.

Commercially, the results could translate into a blockbuster launch. Servier’s $210 million upfront investment and up to $320 million in milestone commitments underscore confidence in the drug’s upside. Analysts project peak annual sales of $800 million, outpacing competitors like Delcath’s Hepzato, which generated roughly $80 million in 2025. Assuming a successful filing later this year, IDEAYA could secure a first‑in‑class label, reshape treatment algorithms, and deliver substantial returns for shareholders while addressing a dire clinical need.